2-Phenylindoles with sulfur containing side chains. Estrogen receptor affinity, antiestrogenic potency, and antitumor activity

Journal of Steroid Biochemistry and Molecular Biology

Volumn 58, Issue 1, 1996, Pages 31-43

  Biberger, C ^a   Von Angerer, E ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; INDOLE DERIVATIVE; SULFONE DERIVATIVE; UNCLASSIFIED DRUG; ZK 164015;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CATTLE; CONTROLLED STUDY; NONHUMAN; UTERUS;

ANIMALIA; BOS TAURUS; MINK CELL FOCUS-FORMING VIRUS;

EID: 0030130570     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-0760(96)00004-0     Document Type: Article

References (32)

1. 1. Maas H., Jonat W., Stolzenbach G. and Trams G.: The problem of nonresponding estrogen receptor-positive patients with advanced breast cancer. Cancer 46 (1980) 2783-2787.
2. 2. Furr B. J. A. and Jordan V. C.: The pharmacology and clinical uses of tamoxifen. Pharmac. Ther. 25 (1984) 127-205.
3. 3. Black L. J. and Goode R. L.: Uterine bioassay of tamoxifen, trioxifene and a new estrogen antagonist (LY 117018) in rats and mice. Life Sci. 26 (1980) 1453-1458.
4. 4. Gottardis M. M., Jiang S. Y., Jeng M. H. and Jordan V. C.: Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res. 49 (1989) 4090-4093.
5. 5. Brünner N., Frandsen T. L., Holst-Hansen C., Bei M., Thompson E. W., Wakeling A. E., Lippman M. E. and Clarke R.: MCF7/LCC2: A 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res. 53 (1993) 3229-3232.
6. 6. Wakeling A. E.: The future of new pure antiestrogens in clinical breast cancer. Breast Cancer Res. Treat. 25 (1993) 1-9.
7. 7. Howell A., DeFriend D., Robertson J., Blamey R. and Walton P.: Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 345 (1995) 29-30.
8. 8. Stein R. C., Dowsett M., Cunningham D. C., Davenport J., Ford H. T., Gazet J.-C., von Angerer E. and Coombes R. C.: Phase I/II study of the antiestrogen zindoxifene (D 16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I/II Clinical Trials Commitee study. Br. J. Cancer 61 (1990) 451-453.
9. 9. von Angerer E., Knebel N., Kager M. and Ganß B.: 1-Aminoalkyl-2-phenylindoles as novel pure estrogen antagonists. J. Med. Chem. 33 (1990) 2635-2640.
10. 10. Nishino Y., Schneider M. R., Michna H. and von Angerer E.: Pharmacological characterisation of a novel oestrogen antagonist, ZK 119010, in rats and mice. J. Endocrinol. 130 (1991) 409-414.
11. 11. von Angerer E., Biberger C., Holler E., Koop R. and Leichtl S.: 1-Carbamoylalkyl-2-phenylindoles: Relationship between side chain structure and estrogen antagonism. J. Steroid Biochem. Molec. Biol. 49 (1994) 51-62.
12. 12. Wakeling A. E. and Bowler J.: Novel antioestrogens without partial agonist activity. J. Steroid Biochem. 31 (1988) 645-653.
13. 13. Wakeling A. E., Dukes M. and Bowler J.: A potent specific pure antiestrogen with clinical potential. Cancer Res. 51 (1991) 3867-3873.
14. 14. Nique F., Van de Velde P., Brémaud J., Hardy M., Philibert D. and Teutsch G.: 11β-amidoalkoxyphenyl estradiols, a new series of pure antiestrogens. J. Steroid Biochem. Molec. Biol. 50 (1994) 21-29.
15. 15. Poirier D., Auger S., Mérand Y., Simard J. and Labrie F.: Synthesis and antiestrogenic activity of diaryl thioether derivatives. J. Med. Chem. 37 (1994) 1115-1125.
16. 16. Auger S., Merand Y., Pelletier J. D., Poirier D. and Labrie F.: Synthesis and biological activities of thioether derivatives related to the antiestrogens tamoxifen and ICI 164384. J. Steroid Biochem. Molec. Biol. 52 (1995) 547-565.
17. 17. Meyer T., Koop R., von Angerer E. and Holler E.: A rapid luciferase transfection assay for transcription activation effects and stability control of estrogenic drugs in cell culture. J. Cancer Res. Clin. Oncol. 120 (1994) 359-364.
18. 18. Tora L., White J., Brou C., Tasset D., Webster N., Scheer E. and Chambon P.: The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 59 (1989) 477-487.
19. 19. Klein-Hitpaß L., Schorpp M., Wagner U. and Ryffel G. U.: An estrogen-responsive element derived from the 5' flanking region of Xenopus vitellogenin A2 gene functions in transfected human cells. Cell 46 (1986) 1053-1061.
20. 20. Klein-Hitpaß L., Kaling M. and Ryffel G. U.: Synergism of closely adjacent estrogen-responsive elements increases their regulatory potential. J. Mol. Biol. 201 (1988) 537-544.
21. 21. von Angerer E., Prekajac J. and Strohmeier J.: 2-Phenylindoles. Relationship between structure, estrogen receptor affinity, and mammary tumor inhibiting activity in the rat. J. Med. Chem. 27 (1984) 1439-1447.
22. 22. Bradford M. M.: A rapid and sensitive method for quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248.
23. 23. Richter A., Sandford K. K. and Evans V. J.: Influence of oxygen and culture medium on plating efficiency in some mammalian tissue culture cells. J. Natl. Cancer Inst. 49 (1972) 1705-1712.
24. 24. Newton C. J., Trapp T., Pagotto U., Renner U., Buric R. and Stalla G. K.: The oestrogen receptor modulates growth of pituitary tumour cells in the absence of exogenous oestrogen. J. Mol. Endocrinol. 12 (1994) 303-312.
25. 25. Cho H., Aronica S. M. and Katzenellenbogen B. S.: Regulation of progesterone receptor gene expression in MCF-7 breast cancer cells: A comparison of the effects of cyclic adenosine 3′,5′-monophosphate, estradiol, insulin-like growth factor-I, and serum factors. Endocrinology 134 (1994) 658-664.
26. 26. Smith C.L., Conneely O.M. and O'Malley B.W.: Estrogen receptor activation by ligand-dependent and ligand-independent pathways. In Steroid hormone receptors: basic and clinical aspects (Edited by V. K. Moudgil). Birkhäuser, Boston (1993) pp. 333-356.
27. 27. von Angerer E., Biberger C. and Leichtl S.: Studies on heterocycle-based pure estrogen antagonists. Ann. N. Y. Acad. Sci. 761 (1995) 176-191.
28. 28. de Launoit Y., Kiss R., Danguy A. and Paridaens R.: Effect of ovariectomy, hypophysectomy and/or GnRH analog (HRF) administration on the cell proliferation of the MXT mouse hormone-dependent mammary tumor. Eur. J. Cancer Clin. Oncol. 24 (1987) 1443-1450.
29. 29. Knebel N. G. and von Angerer E.: 2-Phenylindole linked (2-aminoalkylpyridine)dichloroplatinum(II): complexes with a selective action on estrogen receptor positive mammary tumors. J. Med. Chem. 34 (1991) 2145-2152.
30. 30. Milovanovic S. R., Radulovic S. and Schally A. V.: Evaluation of binding of cytotoxic analogs of luteinizing hormone-releasing hormone to human breast cancer and mouse MXT mammary tumor. Breast Cancer Res. Treat. 24 (1992) 147-158.
31. 31. Hartmann R. W., Bayer H. and Grün G.: Aromatase inhibitors. Syntheses and structure-activity studies of novel pyridyl-substituted indanones, indans, and tetralins. J. Med. Chem. 37 (1994) 1275-1281.
32. 32. Tanaka M., Yano S., Hasegawa Y. and Nakao K.: Antiproliferative effect of the new aromatase inhibitor fadrozole on pre-and postmenopausal models of rat mammary tumor. Arzneimittelforschung 44 (1994) 774-778.